» Articles » PMID: 15110329

Fabry Disease: Reduced Activities of Respiratory Chain Enzymes with Decreased Levels of Energy-rich Phosphates in Fibroblasts

Overview
Journal Mol Genet Metab
Specialty Endocrinology
Date 2004 Apr 28
PMID 15110329
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Fabry disease (FD, MIM 301500) caused by a deficient activity of alpha-galactosidase A is characterized by intralysosomal storage of glycosphingolipids. Main clinical features are paresthesia, hypohidrosis, angiokeratoma, renal insufficiency, and cardiovascular or cerebral complications. The exact pathogenesis is unclear. Beside mechanical storage biochemical factors might play a role. As FD is a multisystemic disorder and mitochondrial dysfunction has been described in patients with neuronal ceroidlipofuscinosis (another lysosomal storage disease) we examined mitochondrial function in fibroblasts from patients with FD.

Results: Activities of respiratory chain enzymes I, IV, and V were significantly (p < 0.01) lower in FD-cells. Mitochondrial recovery was unchanged as judged by the activity of the mitochondrial marker enzyme citratesynthase, cellular protein content was not significantly different. CP, ADP, and AMP concentrations were significantly (p < 0.01) lower in FD-cells. ATP was slightly, but not significantly reduced (p = 0.045).

Conclusion: Organ dysfunction in FD may not only be explained by mechanical storage of glycosphingolipids. As in NCL, lysosomal storage material may lead to mitochondrial dysfunction with a reduction of respiratory chain enzyme activities and a subsequent drop in cellular levels of energy-rich phosphates.

Citing Articles

Lectin-Based Substrate Detection in Fabry Disease Using the Gb3-Binding Lectins StxB and LecA.

Elcin-Guinot S, Lagies S, Avi-Guy Y, Neugebauer D, Huber T, Schell C Int J Mol Sci. 2025; 26(5).

PMID: 40076891 PMC: 11900420. DOI: 10.3390/ijms26052272.


Human in vitro models for Fabry disease: new paths for unravelling disease mechanisms and therapies.

Borisch C, Thum T, Bar C, Hoepfner J J Transl Med. 2024; 22(1):965.

PMID: 39449071 PMC: 11515389. DOI: 10.1186/s12967-024-05756-w.


2024 Update of the TSOC Expert Consensus of Fabry Disease.

Hung C, Wu Y, Kuo L, Sung K, Lin H, Chang W Acta Cardiol Sin. 2024; 40(5):544-568.

PMID: 39308653 PMC: 11413953. DOI: 10.6515/ACS.202409_40(5).20240731A.


The Heart in Fabry Disease: Mechanisms Beyond Storage and Forthcoming Therapies.

Pieroni M, Ciabatti M, Graziani F, Camporeale A, Saletti E, Lillo R Rev Cardiovasc Med. 2024; 23(6):196.

PMID: 39077177 PMC: 11273771. DOI: 10.31083/j.rcm2306196.


The role of tubular cells in the pathogenesis of Fabry nephropathy.

Rozenfeld P, Feriozzi S, Braun F Front Cardiovasc Med. 2024; 11:1386042.

PMID: 38646152 PMC: 11027898. DOI: 10.3389/fcvm.2024.1386042.